Temperature dependency of immunoglobulin production in novel human partner cell line
© Kaseko et al.; licensee BioMed Central Ltd. 2013
Published: 4 December 2013
A number of immunoglobulin (Ig) secreting human hybrid cell lines were created using one-on-one somatic cell hybridization of a rare human tumor infiltrating B lymphocyte and a cell of a novel human cell line (WTM), developed in house and described earlier . These hybrid cell lines secret various amounts of tumor-derived immunoglobulins (Igs) of different specificities. Current investigative efforts are directed towards determining the optimal culture conditions to ensure consistent cell growth and long-term stabilities of Ig productions by the hybrids. Based on previous literature reports [2, 3], we investigated an effect of short- and long-term mild hypothermic conditions on Ig production, cell growth and cell size.
Three different hybrid cell lines each representing the highest, medium and lowest ranges of Ig productions, were subject to culture temperature drops from 37°C to 36°C, 35°C or 34°C for up to 168 hours with 24-hour data point intervals. In case of prolonged mild hypothermia, the cell line with Ig production most susceptible to temperature drops was maintained at various temperatures below 37°C (e.g. 36°C, 35°C and 34°C) for at least 5 passages with each passage lasting 120 hours and the data taken at a 24-hour interval. At each data point for each of the hybrid cell lines at a given temperature interval, the sample was collected to determine cell concentration, cell size and Ig production.
Effects of prolonged mild hypothermia on Ig production by hybrid cell line 2 at day 5 of each passage over 5 passages.
In conclusion, whilst lowering temperature in the culture resulted in overall increase in Ig concentration, our results suggest that there might be different mechanisms responsible for the increase in Ig productivity in response to short temperature drop and prolonged hypothermia.
The project was financially supported in part by Anthrocell Pty Limited, an Australian biotechnology company located in Sydney, Australia.
- Kaseko G, Liu M, Li Q, Mahaworasilpa T: Novel partner cell line for immortalisation of rare antigen-specific B cells in mAb development. BMC Proceedings. 2011, 5 (Suppl 8): P130-PubMed CentralView ArticlePubMedGoogle Scholar
- Chong SL, Mou DG, Ali AM, Lim SH, Tey BT: Cell growth, cell-cycle progress, and antibody production in hybridoma cells cultivated under mild hypothermic conditions. Hybridoma. 2008, 27: 107-111.View ArticlePubMedGoogle Scholar
- Lloyd DR, Holmes P, Jackson LP, Emery N, Al-Rubeai M: Relationship between cell size, cell cycle and specific protein productivity. Cytotechnology. 2000, 34: 59-70.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.